Government, Policy & Advocacy

The American Academy of Child and Adolescent Psychiatry (AACAP) is a major US professional medical association representing child and adolescent psychiatrists and publisher of the Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP). The organization and its journal have actively engaged with questions around psychedelic-assisted therapy for youth, publishing clinical research and ethical analyses on the potential use of psilocybin and MDMA in adolescent populations.

US professional psychiatric body that publishes position statements and guidance relevant to evidence standards and clinical policy considerations for psychedelic and empathogenic therapies.

The Association for Psychedelic Science and Therapy Austria connects mental health professionals and improves public awareness of safe, ethical, evidence-based psychedelic therapies.

Founded in 2020, the Autistic Psychedelic Community (APC) is a Los Angeles-based peer support and co-learning network focused on the intersection of psychedelics and neurodivergent conditions including autism and ADHD, offering psychedelic integration support, panel discussions with researchers, and academic partnerships. Cited in peer-reviewed research, the APC promotes neurodiversity-affirming approaches to psychedelic practice and safe access.

Pharmaceutical company responsible for LUMRYZ REMS implementation in the U.S., including prescriber and pharmacy certification and controlled distribution safeguards.

Longstanding non-profit foundation supporting and convening psychedelic and drug-policy research programs.

Biopharmaceutical company responsible for BRIXADI REMS implementation in the U.S., with certified provider and pharmacy requirements and controlled outpatient distribution pathways.

Canadian public HTA and reimbursement review body supporting evidence appraisal for access decisions.

Canada�s federal health research funding agency setting national biomedical and health-services research priorities.

Policy-focused organization producing legislative analysis and implementation guidance on affordable, state-regulated psychedelic care pathways.

U.S. national public health agency responsible for surveillance, risk communication, and epidemiologic guidance.

The Centre for Evidence Based Drug Policy is a UK think tank promoting evidence-based drug policy to reduce harm, improve public health, and unlock medical and economic benefits.

Cepda is a Danish non-profit think tank working on psychedelic education, community building, advocacy, and research collaboration among professionals, researchers, and people with lived experience.

Nonprofit platform focused on psychedelic education, cultural justice, and Indigenous reciprocity with programming at the intersection of ethics, policy, and community knowledge.

The Chief Scientist Office (CSO) of the Scottish Government funds NHS and health research across Scotland, and has supported University of Edinburgh evaluability work on ketamine-assisted therapy and the development of the Scottish Psychedelic Research Group to build Scotland’s capacity for psychedelic-assisted therapy studies.

Washington state coalition advocating supervised psilocybin access legislation and coalition-based policy campaigns for veterans, first responders, and affected communities.

Colorado Division of Professions and Occupations program overseeing facilitator licensing, renewals, complaints, and rule/policy resources for natural medicine services.

Colorado Department of Revenue division responsible for licensing and regulating natural medicine businesses, including healing centers, cultivations, product manufacturers, and testing facilities.

Statutorily created Colorado advisory board providing implementation recommendations for natural medicine regulation, safety standards, licensing architecture, and program oversight priorities.

Bipartisan U.S. congressional caucus focused on advancing evidence-informed psychedelic policy pathways, with a recurring emphasis on veterans mental health and federal research support.

U.S. federally directed defense-health research program office administering targeted grants, including mental-health priorities.

Brazil's National Council for Scientific and Technological Development (CNPq) is the country's primary public funding agency for scientific research, providing grants, scholarships, and R&D support to universities and research institutions nationwide. CNPq ranks among the top global funders of psychedelic science, having supported seminal ayahuasca clinical trials, pharmacological studies, and productivity fellowships for researchers who established Brazil as a world leader in psychedelic psychiatry.

CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) is Brazil's federal agency for graduate education improvement, providing scholarships, postdoctoral fellowships, and institutional research grants to universities nationwide. Ranked among the top-six global funders of psychedelic research in a 2023 Scopus analysis, CAPES has financed ayahuasca neuroscience studies, clinical investigations, and postdoctoral programmes that underpin Brazil's internationally recognised psychedelic research ecosystem.

The Czech Health Research Council (AZV ČR) is an organisational component of the Czech Ministry of Health responsible for funding applied health research, distributing over 1 billion CZK annually across approximately 90 supported projects per year. It provided the primary grant for the PSIKET001 trial — a landmark double-blind comparison of psilocybin versus ketamine for treatment-resistant depression at the National Institute of Mental Health — with a total budget of 12 million CZK.

Grassroots campaign network focused on decriminalizing entheogenic plants and fungi through local policy campaigns, public education, and community organizing.

US nonprofit policy advocacy organization working to end the war on drugs through legislation, research translation, and public education, including reforms related to psychedelic policy and decriminalization.

Drug Science is a UK-based independent scientific body that supports evidence-led drug policy and public education, and has played a visible role in psychedelic research translation, communication, and policy discourse.

The European Association for Palliative Care (EAPC) is the leading European professional body for palliative care research, education, and policy, headquartered in Milan. The EAPC is a core consortium partner in PsyPal, the first EU-funded multi-site psilocybin clinical trial (€6.5M), studying psilocybin-assisted therapy for psychological distress in patients with COPD, MS, ALS, and atypical Parkinson's disease across multiple European sites.

The European Federation of Neurological Associations (EFNA) is a Brussels-based umbrella organization representing 21 pan-European neurology patient groups, advocating for improved access and resources for people with neurological disorders. EFNA participates as a patient advocacy partner in the PsyPal consortium, the first EU-funded multi-site psilocybin clinical trial (€6.5M) studying psilocybin for psychological distress in palliative care neurological patients.

EU public health agency focused on disease surveillance, risk assessment, and evidence dissemination for member states.

EU medicines regulator for scientific review and pharmacovigilance, including psychiatric products with psychedelic relevance.

EU public drugs observatory and surveillance body publishing trend and risk evidence including hallucinogen/psychedelic monitoring.

Germany’s highest joint self-governing HTA decision body for coverage and evidence appraisal, including esketamine/Spravato dossiers.

Fundación inawe is a Spanish non-profit promoting mental health innovation by developing an ecosystem for implementing psychedelic-assisted therapies in Spain.

The German Federal Ministry of Education and Research (BMBF) is the pioneering Western government funder of large-scale psychedelic clinical trials, having provided approximately €5 million to the EPIsoDE study — the first government-funded Phase 2 psilocybin trial for treatment-resistant major depression — conducted at the Central Institute for Mental Health in Mannheim and Charité Berlin. Germany subsequently became the first EU country to establish a psilocybin compassionate access program for treatment-resistant depression.

The German Society for Psychedelic Research and Therapy is a professional association for physicians, psychologists, and other professionals supporting scientific work and potential clinical introduction of psychedelic therapies.

HYSTELICA is a non-profit researching, advocating, and educating for safe and effective psychedelic use for women, with a focus on ensuring women-specific needs shape the future of psychedelics.

Heal Ukraine Trauma is a U.S.-based non-profit providing evidence-based mental health support to Ukrainian veterans and their families healing from war trauma.

Nonprofit campaign and implementation-support organization focused on expanding and protecting safe, affordable, state-regulated psychedelic therapy access, including Oregon and Colorado programs.

Canadian federal health regulator administering controlled access and oversight pathways relevant to psychedelic therapies.

The Health Research Board (HRB) is Ireland's primary statutory health research funding agency, which has awarded grants to Trinity College Dublin's Psychedelic Research Group to investigate psychedelics' immune effects in depression and the feasibility of psilocybin for cocaine-use disorder. The HRB also funds the KARMA-DEP(2) ketamine trial for treatment-resistant depression at St Patrick's University Hospital in Dublin, making it a key enabler of Ireland's emerging psychedelic medicine ecosystem.

Veteran-serving nonprofit supporting access to psychedelic programs and advocating policy pathways that expand safe treatment options for veterans and their families.

Heroic Hearts UK connects UK military and emergency services veterans with psychedelic therapy retreat centres in countries where those practices are legal.

HoloMind is a Polish initiative educating the public about therapeutic psychedelic use and advocating for psychedelic treatments in Poland.

Nonprofit organization supporting evidence, policy, and community-centered programs around psychedelic plants, including Indigenous reciprocity and traditional knowledge initiatives.

IHPI (Ibogaine Healthcare Policy Institute) is a 501(c)(3) nonprofit building policy infrastructure for regulated ibogaine care in the United States. Its work focuses on decision-grade resources for healthcare leaders, including safety and delivery standards, regulatory pathways, reimbursement mechanics, payment/coding roadmaps, coverage criteria, and implementation planning. The organization was founded on 1 January 2026 and is incubated by Delphi.

Icelandic Psychedelic Society - Hugvikkandi is a platform for people interested in psychedelics to build community, strengthen advocacy, educate themselves, support research and legal progress, and collaborate internationally.

Independent multidisciplinary working group assessing evidence-evaluation frameworks for psychedelic therapies to inform regulators and policy design.

Pharmaceutical company responsible for the U.S. SUBLOCADE REMS program, including enrollment, certified healthcare setting controls, and controlled dispensing requirements.

Institut National de la Santé et de la Recherche Médicale (INSERM) is France's national public health and medical research agency, funding and conducting biomedical research across university-hospital institutes throughout the country. INSERM-affiliated researchers at the Paris Brain Institute (ICM) and Pitié-Salpêtrière Hospital have contributed to preclinical and clinical investigations of ketamine and psilocybin as rapid-acting antidepressants.

Instituto Mexicano del Seguro Social (IMSS) is Mexico's largest social security institute, operating the country's most extensive public hospital and clinic network serving over 70 million workers and their families. An IMSS-affiliated facility has participated in clinical research on ketamine for treating depressive symptoms in elderly patients with visual impairment.

Instituto de Salud Carlos III (ISCIII) is Spain's national public health research agency, managing the CIBERSAM network (Centro de Investigación Biomédica en Red de Salud Mental) which co-funds biomedical mental health research across Spanish universities and hospitals. Through CIBERSAM, ISCIII has co-funded preclinical and translational research on psilocybin as an antidepressant and supports researchers contributing to the European psychedelic therapy landscape.

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE) is Mexico's federal social security institute for government employees, operating a nationwide network of hospitals and clinics serving millions of public-sector workers and their families. An ISSSTE-affiliated facility has participated in clinical research examining ketamine's effect on depressive symptoms in elderly patients with visual impairment.

The International Alliance of MDMA Practitioners (MDMA Alliance) is a professional network focused on standards, training, and shared learning for MDMA-assisted therapy practitioners and allied clinicians.

Irish Doctors for Psychedelic Assisted Therapy is a non-profit improving awareness of psychedelic research among clinicians and policymakers and advocating for state-funded psychedelic research trials.

Istituto Superiore di Sanità (ISS) is Italy's National Institute of Health, the country's principal technical and scientific public body for biomedical research, public health surveillance, and regulatory advisory functions. The institute has participated in pharmacological research on designer psychoactive substances including methylone, an MDMA analogue, contributing to Italy's evidence base for novel psychoactive substance regulation.

SIMEPSI is an Italian multidisciplinary non-profit promoting psychedelic research, cultural awareness, regulatory frameworks for safe treatments, knowledge exchange, and public education.

Pharmaceutical sponsor operating SPRAVATO REMS restricted-distribution controls for supervised administration, site certification, and patient enrollment in the US market.

Biopharmaceutical company that administers the U.S. XYWAV and XYREM REMS restricted distribution program, including certification, dispensing controls, and program reporting requirements.

Kykeon works to destigmatize psychedelics in Greece through community building, education, interdisciplinary dialogue on therapeutic use, and drug policy reform advocacy.

Luca Coscioni Association works with experts, researchers, and scientists to prepare technical documents supporting legislative, judiciary, and policy proposals and amendments.

Long Alliantie Nederland (Lung Alliance Netherlands) is the Dutch national patient alliance representing people with lung diseases including COPD, asthma, and pulmonary fibrosis; as one of 19 consortium partners in the EU Horizon Europe–funded PsyPal trial (€6.5M), the Alliance contributes patient expertise for the COPD arm investigating psilocybin therapy for psychological distress in palliative care.

Nonprofit organizer and host of the Psychedelic Science conference series, alongside broader educational and policy programming.

The Amsterdam-based European subsidiary of MAPS (Multidisciplinary Association for Psychedelic Studies), MAPS Europe B.V. was established in 2018 to advance MDMA-assisted psychotherapy through EMA-regulated Phase 2 and Phase 3 clinical trials for PTSD across Europe. The organization ran the first multi-site European MDMA/PTSD Phase 2 open-label study with sites in London, Berlin, Lisbon, and others, and trained therapists from 14 countries.

MAPS Italia is a non-profit founded in 2024 to support informed dialogue, education, research, and advocacy for therapeutic uses of psychedelic substances in Italy.

UK medicines regulator overseeing trial authorizations, pharmacovigilance, and market-authorization pathways.

Australian registered charity founded in 2019 that successfully campaigned for the Therapeutic Goods Administration (TGA) to reschedule psilocybin and MDMA in 2023 — making Australia the first country to formally approve these substances for clinical use. MMA trains clinicians through its Certificate in Psychedelic-Assisted Therapies (CPAT) program, funds clinical trials, and has supplied medicines and training to 100+ patients under the TGA Authorised Prescriber scheme.

The National Association for Psychedelic Research in Serbia promotes education, dialogue, and research advocacy around psychedelics in mental health, translating scientific findings for professionals and the public.

The National Cancer Institute (NCI) is the principal US federal agency for cancer research and training, one of 27 institutes within the National Institutes of Health, with an annual budget exceeding $7 billion. In the psychedelic field, NCI has supported trials exploring psilocybin-assisted therapy for cancer-related demoralization and chronic pain in survivors, as well as ketamine infusion to prevent depression in patients undergoing treatment for pancreatic and head-and-neck cancers.

NIH center that accelerates the translation of biomedical discoveries into health solutions. NCATS' Clinical and Translational Science Awards (CTSA) program funds the infrastructure at academic medical centers that supports emerging research including psychedelic-assisted therapy trials.

U.S. federal institute focused on complementary/integrative research and evidence programs including psychedelic-adjacent contexts.

The National Center for PTSD (NC-PTSD) is a US Department of Veterans Affairs centre of excellence for research, education, and training on post-traumatic stress disorder, operating across seven VA medical centre sites with a focus on evidence-based assessment and treatment. The Centre has supported mechanistic ketamine research in military and veteran populations, including an investigation of AMPA receptor blockade on ketamine’s anti-suicidal effects relevant to veteran mental health crises.

The National Center for Research Resources (NCRR) was a National Institutes of Health centre that funded biomedical research infrastructure, clinical and translational science programmes, and shared research resources until its dissolution in 2011, when its programmes were reorganised primarily into the new National Center for Advancing Translational Sciences (NCATS). NCRR infrastructure and clinical research awards supported early NIH-funded investigations into glutamate-modulating medications for major depressive disorder that laid the mechanistic groundwork for understanding ketamine’s rapid antidepressant effects.

Ireland’s national HTA and pharmacoeconomics body that conducts rapid review and full HTA for reimbursement decisions, including esketamine references.

The National Council of Scientific and Technical Research (CONICET; Consejo Nacional de Investigaciones Científicas y Técnicas) is Argentina’s principal government agency for promoting science and technology, funding over 11,000 researchers and 10,000 doctoral students across a nationwide network of research institutes and centres. CONICET supported the NATMICRO study, a naturalistic observational investigation of the psychological and cognitive effects of self-administered psilocybin microdosing conducted in Argentina.

UK public health research funder and implementation infrastructure supporting NHS-oriented evidence generation.

UK HTA body issuing evidence and cost-effectiveness recommendations that influence medicine access.

U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is a US National Institutes of Health institute dedicated to research on alcohol use disorder and its public health impacts, supporting approximately $500 million in research annually. NIAAA has funded studies exploring both ketamine administration for acute alcohol use disorder in the emergency department and psilocybin-assisted therapy to understand the neurobehavioral mechanisms underlying alcohol use disorder treatment.

U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.

U.S. federal biomedical research agency shaping institute-level priority and research funding architecture.

The National Network of Depression Centers (NNDC) is a US non-profit consortium of academic medical centres united to advance the prevention, diagnosis, and treatment of mood disorders through collaborative research, clinical programmes, and policy advocacy, with member institutions spanning more than 25 major academic health systems. The NNDC supported the BIO-K study, an open-label biomarker development trial investigating intravenous ketamine for non-psychotic unipolar major depression and bipolar I/II depression.

New Mexico state health authority responsible for implementation and oversight of the Medical Psilocybin Act program.

Oregon state health authority administering Oregon Psilocybin Services licensing and implementation oversight.

State-level Oregon pharmacy and therapeutics decision body supporting evidence-driven formulary and utilization policy.

State advisory board charged with issuing recommendations to Oregon Health Authority on psilocybin services implementation, professional standards, public health safeguards, and operational controls.

Australia’s HTA and reimbursement advisory body for PBS listing decisions, including esketamine (Spravato) assessment materials.

The Polish Psychedelic Society popularizes and supports scientific research on psychedelic substances and provides space for debate about their application in science, medicine, psychotherapy, and culture.

Psilocybin Access Rights is a volunteer campaign pressing the UK government to reschedule psilocybin and make it accessible for patients and researchers.

EU-wide European Citizens’ Initiative campaigning for standardized psychedelic therapy guidelines, expanded EU research funding, and aligned international legal classification policy.

European multi-stakeholder alliance coordinating advocacy, policy dialogue, and member working groups to improve access, reimbursement, and responsible integration of psychedelic therapies.

Psychedelic Coalition for Health (PCH) is a clinician-led psychedelic medicine education and advocacy organization co-founded by psychotherapists Lauren Taus and Nicholas Brüss, offering psychedelic-assisted therapy training, virtual symposia, and scholarship programs for healthcare professionals. PCH trains licensed clinicians in ketamine, MDMA, and IFS-informed approaches while advocating for equitable access to and responsible implementation of psychedelic medicine.

Washington, D.C.-based nonprofit advocacy organization focused on federal and state psychedelic policy, lawmaker education, and coalition-building for safe and equitable access.

US political action organization supporting candidates and policy movements that advance evidence-based psychedelic medicine access and rescheduling at state and federal levels.

PRISM is an Australian nonprofit organization advancing evidence-based psychedelic science, policy, and public education through research communication, expert engagement, and policy-facing advocacy.

Belgium-based nonprofit community organization advancing psychedelic public education, events, and informed dialogue through outreach activities.

European advocacy platform convening policymakers, regulators, researchers, and businesses to develop EU regulatory pathways for psychedelic therapies.

Canada�s national public health agency responsible for surveillance, risk assessment, and public-health guidance.

Reconnect Foundation is a Swiss non-profit supporting consciousness research, mental health care accessibility, and Indigenous stewardship of ecosystems and biodiversity.

UK drugs policy and legal reform organization advancing rights-based drug policy change, including evidence-led approaches relevant to psychedelic policy and access.

Regional psychiatric college issuing clinical memoranda and implementation guidance on psychedelic-assisted therapy, including MDMA and psilocybin use in regulated psychiatric contexts.

Salt City Psychedelic Therapy and Research (SCPTR) is a Utah-based nonprofit founded by the late Dr. Parth Gandhi to advance psychedelic-assisted therapy through education, research, and advocacy in the Intermountain West. SCPTR organizes the annual Intermountain Psychedelic Symposium and supports practitioners, researchers, and policy reform in the region.

SPACE is a Portuguese scientific association founded in 2021 by psychiatry doctors to study, disseminate, and promote knowledge about the potential therapeutic uses of psychedelic substances.

Scotland’s public HTA body issuing medicine acceptance guidance, including esketamine (Spravato) advice.

The Société Psychédélique Française is a French hub for young researchers, students, scientific and cultural mediation, and community discussion grounded in responsibility and harm reduction.

SEMPsi brings together medical doctors, psychologists, and mental health researchers to promote evidence-based psychedelic therapy and research in an ethical, scientific, and culturally respectful context.

Global youth-led network advocating evidence-based drug policy reform through campus organizing, policy campaigns, and public education that include psychedelic reform issues.

U.S. national public health agency for behavioral health policy and surveillance, including hallucinogen and ketamine epidemiology in national datasets.

Swiss federal authority issuing exceptional licences for otherwise prohibited narcotics, including controlled pathways relevant to psychedelic substances under medical/scientific exceptions.

The Swiss Medical Association for Psychedelic Therapy (SÄPT) is a Switzerland-based professional medical association focused on clinical standards, practitioner community building, and responsible development of psychedelic-assisted therapy.

Swiss medical society founded in 1985 whose members received special permission from the Swiss Federal Office of Public Health to conduct psychedelic-assisted therapy with MDMA and LSD in private practices from 1988 to 1993, treating approximately 170 patients. SÄPT continues to advance psycholytic therapy through research, training, and individual treatment licenses, and sponsored the LSD-Assist Study demonstrating persistent anxiety reductions at two-year follow-up.

U.S. shared-system REMS program for transmucosal immediate-release fentanyl products, maintaining restricted prescriber, pharmacy, and patient enrollment controls.

Texas state health agency overseeing policy functions and implementation of psychedelic-adjacent public initiatives such as ibogaine programs.

Australian national regulator for scheduling, prescribing pathways, and safety oversight including MDMA/psilocybin psychiatry contexts.

TheraPsil is a Canadian grassroots nonprofit advancing compassionate, legal access to psilocybin-assisted psychotherapy through clinician training, patient advocacy, and legal reform, having trained over 700 healthcare professionals since 2019. The organization assists Canadians in navigating Health Canada's Special Access Program, supports patient-rights litigation in Federal Court, and operates the PsilWell community-funded clinical trial exploring psilocybin-assisted therapy for general wellbeing.

UK-based policy foundation supporting evidence-driven drug policy reform, including psychedelic policy pathways.

U.S. federal veterans health authority with explicit psychedelic-adjacent clinical research and care-implementation activity through VA research and care networks.

US federal regulator for drug development and safety oversight, including psychedelic clinical-investigation pathways.

UK national public health agency responsible for surveillance and population-risk evidence, including substance-harm monitoring referenced in ketamine policy review.

The Ukrainian Psychedelic Research Association convenes academics, clinicians, patients, and activists to advance legal therapeutic use and scientific psychedelic research in Ukraine.

U.S. Veterans Affairs research authority overseeing national veteran-focused clinical research programs including psychedelic-adjacent initiatives.

Veteran-led nonprofit coalition advocating federal and state policy reform to expand access to psychedelic-assisted therapies and reduce veteran suicide.

Veteran-focused nonprofit advocating expanded access to psychedelic-assisted therapies, especially for PTSD and related conditions, through policy engagement and public education.

Washington state health authority overseeing health programs and hosting the state psilocybin task force process under public-health governance structures.

Washington State HTA program conducting evidence review that informs state coverage and utilization policy.

U.S. REMS program for isotretinoin products that enforces pregnancy-prevention controls through prescriber, pharmacy, and patient workflow requirements.